AI biotech remains a compelling market narrative, but the earnings proof is still uneven. Investors are backing machine learning to improve target discovery, molecule design, trial recruitment and regulatory workflows, even though reliably producing breakthrough drugs remains an unsolved challenge. That tension makes the theme especially sensitive to clinical results, partnership economics and evidence that better models can translate into better commercial outcomes.
The structural case rests on pharma’s need to improve research productivity, falling compute and data-generation costs, and growing willingness among large drugmakers to partner with AI-native platforms. The opportunity now stretches beyond drug-discovery software into clinical-trial optimization, automated laboratories, genomics, biomarker analytics and data infrastructure. In July 2026, GSK signed a collaboration with Relation Therapeutics worth up to $110 million, reinforcing that major drugmakers continue to fund AI-enabled discovery despite execution risk.
This countdown runs from #7 to #1. The ranking emphasizes depth of exposure to AI biotech first, then business fundamentals, including revenue growth, profitability, earnings execution, partnerships and analyst expectations. The result is a deliberately broad list: some companies are AI-native discovery platforms, while others participate through genomics, diagnostics, computational chemistry or established therapeutic businesses.
The screen covers US-listed companies with market capitalizations above $500 million and usable exposure to AI biotech or its adjacent data and discovery ecosystems. We ranked them primarily by how directly their products connect to artificial intelligence, computational biology, automation or data-rich drug development, and secondarily by financial quality. Composite quality grades, revenue trends, margins, earnings history and analyst consensus provide the business-fundamentals check. This is a countdown: the best pick is revealed at #1.
Market cap: $0.5B · Quality grade: C · Analyst consensus: Hold (avg target $6)
What they do. The company is a clinical-stage genome-editing business developing CRISPR-based genomic medicines for serious diseases. Its lead program, EDIT-401, is a one-time therapy intended to reduce LDL cholesterol, while the broader pipeline includes sickle cell disease, transfusion-dependent beta thalassemia and other in vivo editing programs; Editas also has a research collaboration with Juno Therapeutics.
Why it fits. Editas is an indirect AI-biotech exposure rather than an AI-native platform. Its relevance comes from the genomics and advanced-biotechnology layer, where large biological datasets and computational tools can support target selection and therapeutic design, but the supplied business description does not identify a standalone AI product.
Numbers that matter. Revenue was $47.005 million, with year-over-year revenue growth of 232.3%, but the company remained deeply unprofitable: gross margin was -80.7%, operating margin was -167.31% and net margin was -157.32%. EBITDA was -$81.035 million, while trailing EPS was -$0.66 and next-year EPS is estimated at -$0.7531. Those figures explain why Editas sits at the bottom of this list despite its potentially transformative therapeutic platform.
Recent momentum. Editas reported August 2026 EPS of -$0.15 versus an estimate of -$0.30, a 50.0% positive surprise, and has beaten estimates in five of the past eight reported quarters. Still, the analyst breakdown is cautious, with one Buy, eight Holds and two Sells; the average analyst target is $6.
Market cap: $1.9B · Quality grade: C · Analyst consensus: Hold (avg target $7.2167)
What they do. The company integrates biology, chemistry, automation, data science and engineering to industrialize drug discovery. Its clinical pipeline includes REC-4881, REC-617, REC-1245, REC-3565 and REC-4539, alongside preclinical programs, while collaborations and agreements with Roche and Genentech, Sanofi, Bayer, Tempus and Takeda extend the platform’s commercial reach.
Why it fits. Recursion is one of the clearest direct matches for the theme because its model explicitly combines automation, data science and engineering with biological and chemical experimentation. Its approach targets the picks-and-shovels problem inside drug discovery: making experiments more systematic and scalable before programs enter the clinic.
Numbers that matter. Revenue was $54.856 million, down 60.1% year over year, and EBITDA was -$471.604 million. Gross margin was -715.7% and operating margin was -1,759.69%, while trailing EPS was -$1.02 and next-year EPS is estimated at -$0.8947. The financial profile remains a major counterweight to the company’s strong thematic exposure.
Recent momentum. August 2026 EPS was -$0.25 versus an estimate of -$0.23, a miss of 8.7%, and Recursion has beaten estimates in four of the past eight quarters. Analysts are mostly on Hold, with one Buy and six Holds; their average target is $7.2167, indicating interest in the platform but limited consensus on near-term execution.
What they do. The company discovers and develops antibody-based medicines for conditions with unmet medical need. Its lead programs include ABCL635 in Phase 2 for vasomotor symptoms and ABCL575 in Phase 1 for T-cell-mediated autoimmune conditions, while collaborations with Eli Lilly, AbbVie, Jazz Pharmaceuticals, Biogen and Vertex support antibody research, development, manufacturing and commercialization.
Why it fits. AbCellera’s connection to AI biotech is best viewed as an adjacent discovery-platform exposure, not a disclosed standalone AI product. Its antibody focus places it in the part of the ecosystem where high-throughput biological information, screening and computational prioritization can help pharmaceutical partners identify and advance candidates.
Numbers that matter. Revenue was $66.17 million, down 76.3% year over year, while reported earnings growth was 45.9%. Profitability remains weak: gross margin was -198.9%, operating margin was -1,550.05% and net margin was -248.84%; EBITDA was -$199.96 million. Trailing EPS was -$0.55, next-year EPS is estimated at -$0.715 and forward P/E was 27.5482.
Recent momentum. AbCellera’s August 2026 EPS of -$0.18 missed the -$0.17 estimate by 5.9%, and its eight-quarter beat rate is four of eight. The analyst breakdown includes two Buys and one Hold, with no Sell rating reported; the average analyst target is $17.125.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. The company develops physics-based computational software for discovering molecules used in drug development and materials applications. Its Software segment sells tools to life sciences and materials customers, while its Drug Discovery segment builds preclinical and clinical programs internally and through collaborations, including a research agreement with Novartis.
Why it fits. Schrödinger is a direct computational-drug-discovery name, giving investors exposure to the software layer that can narrow molecular searches before laboratory and clinical work. Its combination of recurring software activity and internally developed drug programs also provides a broader business model than a single-asset biotechnology company.
Numbers that matter. Revenue reached $259.035008 million, up 7.5% year over year, and gross margin was 56.9%. However, operating margin was -70.55%, net margin was -20.98% and EBITDA was -$147.579008 million. Trailing EPS was -$0.73, with next-year EPS estimated at -$1.35, so the software economics have not yet offset drug-discovery investment.
Recent momentum. The latest quarter produced EPS of $0.08 versus an estimate of -$0.60, a 113.3% positive surprise, although the company has beaten estimates in five of eight quarters. The analyst panel lists two Holds and no reported Buy or Sell ratings; the average target is $21.4286.
What they do. The company provides blood and tissue tests, genomic data sets and software for precision oncology. Its portfolio includes Guardant360 liquid and tissue testing, Guardant Reveal, the Shield colorectal-cancer screening test, GuardantINFINITY, GuardantOMNI, GuardantConnect and the Smart Platform, alongside companion-diagnostic development and other testing services.
Why it fits. Guardant represents the genomics and biomarker-analytics branch of AI biotech. Its multimodal genomic, epigenomic and RNA-based information can support cancer research, therapy development and clinical decisions, while GuardantConnect applies patient and assay information to clinical-trial matching.
Numbers that matter. Revenue was $1.183105024 billion, up 44.3% year over year, and gross margin was 65.0%. The company remained loss-making, with operating margin of -38.25%, net margin of -38.33% and EBITDA of -$430.571008 million. Trailing EPS was -$3.46, while next-year EPS is estimated at -$0.4424, suggesting analysts expect a meaningful reduction in losses but not immediate profitability.
Recent momentum. Guardant reported July 2026 EPS of -$0.89 versus an estimate of -$0.74, a 20.3% miss, and has beaten estimates in four of the past eight quarters. Analysts are constructive overall, with four Buys and one Sell; their average target is $194.2917.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This monthly screen uses primary-source company descriptions, financial statements, earnings histories, analyst consensus and composite quality metrics for US-listed companies with market caps above $500 million. Companies were ranked first by depth of exposure to AI biotech, including AI-native drug discovery, computational chemistry, genomics, diagnostics, biomarker analytics and related data platforms. Business fundamentals then determined the order within comparable levels of thematic exposure, with attention to revenue growth, margins, earnings surprises, valuation and partnership evidence. The list is presented in countdown order and refreshed monthly as new financial and consensus data become available.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
